Quercetin-curcumin co-supplementation reduces overall symptom burden, fatigue, and pain and improves physical health-related quality of life in adults with mild-to-moderate Long COVID.
In an open-label, single-arm exploratory study, 15 adults with Long COVID received a quercetin-curcumin supplement (65 mg quercetin and 42 mg curcumin per capsule, two capsules twice daily) for 8 weeks alongside standard care. Overall symptom burden decreased significantly from a median C19-YRS score of 50 to 32 (q=0.018), with significant reductions in fatigue (q=0.006) and pain severity/interference (q=0.006), and improved physical health-related QoL (SF-36 PCS, q=0.025).
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Quercetin-curcumin co-supplementation reduces overall symptom burden, fatigue, and pain and improves physical health-related quality of life in adults with mild-to-moderate Long COVID. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).
The Claim
Quercetin-curcumin co-supplementation reduces overall symptom burden, fatigue, and pain and improves physical health-related quality of life in adults with mild-to-moderate Long COVID.
This conclusion is most relevant to: Adults with mild-to-moderate Long COVID (persistent symptoms following SARS-CoV-2 infection) in an outpatient real-life clinical practice setting..
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Potential Adjunctive Effects of Quercetin-Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study. (Pharmaceuticals (Basel, Switzerland), 2026) —
How It Works
The proposed biological pathway:
- ▸Quercetin and curcumin exert anti-inflammatory and antioxidant effects by modulating NF-κB and Nrf2 pathways
- ▸They may reduce chronic inflammation and oxidative stress implicated in Long COVID
- ▸Potential senolytic properties may clear virus-induced senescent cells, reducing persistent immune activation
- ▸Result: Reduced symptom burden, fatigue, and pain, and improved physical QoL
Who Might Benefit
Evidence fit by population:
- ▸Adults with mild-to-moderate Long COVID (persistent symptoms following SARS-CoV-2 infection) in an outpatient real-life clinical practice setting.
Recommended Dose
Two capsules twice daily (total daily: 260 mg quercetin, 168 mg curcumin)
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Uncontrolled single-arm open-label design, so observed changes may be due to natural recovery or placebo effects
- ▸Small sample size (n=15) limits generalizability and statistical power
- ▸No placebo control group, and results are exploratory and should be interpreted cautiously
Frequently Asked Questions
What is the recommended dose of quercetin-curcumin for Long COVID?▼
In this study, participants took two capsules twice daily, providing 260 mg quercetin and 168 mg curcumin per day for 8 weeks. However, this is not a recommendation; further trials are needed.
Does quercetin-curcumin improve sleep quality in Long COVID?▼
Sleep quality (PSQI) showed numerically favorable changes but did not reach statistical significance in this study.
Is quercetin-curcumin safe for Long COVID patients?▼
The supplement was generally well tolerated with no serious adverse events reported in this small study.
What are the main benefits of quercetin-curcumin in Long COVID?▼
The study found significant reductions in overall symptom burden, fatigue, and pain, and improved physical health-related quality of life after 8 weeks.
References
- 1.Khan A, Rabbani F, Mumtaz SU, Javed R, Ujjan I, Kanwal A, Conti G. “Potential Adjunctive Effects of Quercetin-Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study..” Pharmaceuticals (Basel, Switzerland), 2026. PMID: 42653699 DOI: 10.3390/ph19081202